SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|
| Celavas | 800 mg | Film-coated tablet · Oral use | 180 Bottle | SAR 452.95 | Generic · Prescription | Alrai Pharmaceutical industry Co. (L.L.C) | Valid |
| Lamsev 800 | 800 mg | Film-coated tablet · Oral use | 180 Bottle | SAR 476.75 | Generic · Prescription | ALTAIF PHARMACEUTICALS COMPANY | Valid |
| RENAPAT | 800 mg | Film-coated tablet · Oral use | 270 Bottle | SAR 475.55 | Generic · Prescription | SUDAIR PHARMA COMPANY | Valid |
| RENOMER 800 MG FILM-COATED TABLET | 800 mg | Film-coated tablet · Oral use | 180 Bottle | SAR 529.75 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| RENVELA 2.4 g powder for oral suspension | 2.4 g | Powder for oral suspension · Oral use | 60 Sachet | SAR 623.25 | NCE · Prescription | GENZYME | Valid |
| RENVELA 800 mg film-coated tablet | 800 mg | Film-coated tablet · Oral use | 180 Tablet Container | SAR 623.25 | NCE · Prescription | GENZYME | Valid |
Indications — CHI Daman Drug Formulary
CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDERS; HYPOPARATHYROIDISM; PEDIATRIC B-CELL LYMPHOMA
US FDA United States — FDA approvals (Drugs@FDA)
3 more — full table
EMA European Union — centrally authorised medicines
Renvela Sanofi Winthrop Industrie · Authorised · authorised 9 Jun 2009 · ATC V03AE02
Therapeutic indication (EMA)
Renvela is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ? 1.78 mmol/l. Renvela should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues to control the development of renal bone disease.
Therapeutic indication (EMA)
Sevelamer carbonate Winthrop is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Sevelamer carbonate Winthrop is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus > 1.78 mmol/L. Sevelamer carbonate Winthrop should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|
| ACCEL-SEVELAMER | 02461501 | 800 MG | TABLET · ORAL | ACCEL PHARMA INC |
| RENVELA | 02354586 | 800 MG | TABLET · ORAL | SANOFI-AVENTIS CANADA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| US NADAC | RENVELA 800 MG TABLET | $5.68515 | per EA | 22 Apr 2026 |
| US NADAC | SEVELAMER CARBONATE 800 MG TAB | $0.214 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.